Quigley Pharma Inc. Enlists Leading Radiation Oncology Researcher To Assist In The Development Plan For Radiological Testing Of QR-336 Compound

DOYLESTOWN, Pa., April 3 /PRNewswire-FirstCall/ -- Quigley Pharma, a wholly owned subsidiary of The Quigley Corporation , announced today that it has signed an agreement with Dr. William H. McBride, the Vice Chair of Research, Department of Oncology at UCLA to help develop an appropriate animal model radio protective research program for QR-336 to comply with New Food and Drug Administration animal efficacy rules for radio- protective pharmacological compounds.

"We are very happy to have a distinguished expert in Dr. McBride involved with the protocol development process," said Dr. Richard Rosenbloom, COO and Executive Vice President. "His experience developing radiological clinical trials makes him uniquely qualified to design the proper studies to test the effectiveness of this compound."

The QR-336 compound has demonstrated encouraging results in a preliminary non-GLP animal study against ionizing radiation. A further in-vivo study involving pre-treating mice with QR-336, followed by lethally irradiating the treated and untreated groups has shown a four-fold increase (80% survival rate) in mice surviving the otherwise lethal dose of radiation as compared to the non-treated group. Results also show that bone marrow extracted from animals that were previously treated with QR-336 and irradiated, could protect another set of irradiated animals whereas bone marrow also extracted from untreated, irradiated mice could not protect lethally irradiated animals.

QR-336 is being investigated to potentially reduce the effects of ionizing radiation, which could affect cancer patients undergoing radiation therapy, nuclear-terrorism (i.e. dirty bomb), the nuclear industry, healthcare professionals as well as commercial airline flight crews. Ionizing radiation has been linked to Leukemia and other pathology. The development of a naturally derived non-toxic drug could potentially offer some protection against these effects

About William McBride, Ph.D.

Dr. McBride is the Vice Chair of Research, at the Department of Radiation Oncology as well as the principal investigator of the UCLA Center for Biological Radioprotectors, which serves as an NIAID - biodefense: Center for Medical Counter Measures Against Radiation. Dr. McBride's far-reaching industry expertise includes participation in a series of meetings under NIH, DHHS, FDA and other government offices designed to determine what animal models make sense for radiation. He was one of the co-authors of the meeting report "Animal Models for Radiation Injury, Protection and Therapy."

Editorial Boards Cancer Immunology Immunotherapy, 1982-1992 Immunology, 1982-1993 Radiation Research, 1992-1996 Cancer Gene Therapy, 1995-Present International Journal Radiation Oncology Biology Physics, 1995-197, 1998- 2000, 2001, 2003, 2005 Occasional referee for papers to: Biotechniques, Blood, Cancer, Cancer Gene Therapy, Cancer Research, Clinical Cancer Research, Clinical Experimental Immunology, European Journal of Cancer, International Journal of Cancer, International Journal Radiation, Oncology Biology Physics, Journal of Cell Biology, Journal of Cellular Immunology, Journal of Clinical Oncology Radiotherapy, Journal of Immunology, Journal of Immunotherapy, Journal of Laboratory Immunology, Metastasis Journal, Molecular Carcinogenesis, Nature, Radiation Oncology Investigations, Radiation Research, Radiotherapy and Oncology. Committee Work International Congress of Radiation Research Program committee, 13th International Congress of Radiation Research, 2005-2007 Radiation Research Society President-Elect, 2005 American Society for Therapeutic Radiology and Oncology Research Council (Vice-Chair), 2003-2005 Grant Assessor and Reviewer (National/International) National Institutes for Health/National Cancer Institute Pathology Study Group, 1980 Cancer Research Manpower Review Committee, 1988-1993, 1995, 1996, 2002 T32 and RO3 Grants Study Section, ad hoc, Washington D.C., 1997 Radiation Study Section Ad hoc, Washington D.C., 1992, 1996 Permanent member 1997-2001 Chair, 2000-2001 Bioshield NIAID Grant Review Committee (Chair), 2004 NCI Program Project Parent Committee D,7 2005-2006, 2008 Department of Energy Department of Defense American Board of Radiology American Society for Therapeutic Radiology and Oncology American Institute of Biological Sciences/US Army Medical Research and Material Command - Panel D Two: Anti-Radiation Drug Development/Tungsten Grant Review Committee, 2005

The Quigley Corporation makes no representation that the U.S. Food and Drug Administration or any other regulatory agency will grant an IND for human study or take any other action to allow the aforementioned compound to be marketed. Furthermore, no claim is made that the potential medicine discussed here is safe, effective, or approved by the Food and Drug Administration.

About The Quigley Corporation

is a diversified natural health medical science company. Its Cold Remedy segment is a leading marketer and manufacturer of the COLD-EEZE(R) family of lozenges, gums and sugar free tablets clinically proven to cut the common cold nearly in half. COLD-EEZE customers include leading national wholesalers and distributors, as well as independent and chain food, drug and mass merchandise stores and pharmacies. The Quigley Corporation has several wholly owned subsidiaries. Darius International markets health and wellness products through its wholly owned subsidiary, InnerLight Inc. Quigley Manufacturing Inc. consists of two FDA approved facilities to manufacture COLD- EEZE(R) lozenges as well as fulfill other contract manufacturing opportunities. Quigley Pharma Inc. (http://www.QuigleyPharma.com) conducts research in order to develop and commercialize a pipeline of patented botanical and naturally derived prescription drugs.

Certain statements in this press release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and involve known and unknown risk, uncertainties and other factors that may cause the company's actual performance or achievements to be materially different from the results, performance or achievements expressed or implied by the forward-looking statement. Factors that impact such forward-looking statements include, among others, changes in worldwide general economic conditions, changes in interest rates, government regulations, and worldwide competition.

All media inquiries for Quigley Pharma and Dr. McBride should be directed to:

CONTACT: Media Investor Relations Karen Pineman Carl Hymans G.S. Schwartz & Co. G.S. Schwartz & Co. 212.725.4500 212.725.4500 kpineman@schwartz.comcarlh@schwartz.com

The Quigley Corporation

CONTACT: Media: Karen Pineman, +1-212-725-4500, kpineman@schwartz.com, orInvestor Relations: Carl Hymans, +1-212-725-4500, carlh@schwartz.com, bothof G.S. Schwartz & Co.

Back to news